Coya Therapeutics (COYA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$8.0M

Revenue (quarter)

$243,745.00

Revenue growth (year over year)

+48.97%

Gross profit (trailing twelve months)

$8.0M

Gross margin

100.00%

Net income (trailing twelve months)

−$21.7M

Net income (quarter)

−$6.6M

Net income growth (year over year)

−8.91%

Net margin

−270.22%

Return on equity

−60.54%

EPS (trailing twelve months)

−$1.07

Book value per share

$1.84

P/E (trailing twelve months)

—

Price to book

2.43

Debt to assets

8.52%

Payout ratio

—

Dividend yield

—

Company profile

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.

• Is Coya Therapeutics (COYA) profitable?

  No. Coya Therapeutics reported a net loss of $21.7M over the trailing twelve months.

• How much revenue does Coya Therapeutics (COYA) make?

  Coya Therapeutics generated $8.0M in revenue over the trailing twelve months, up 48.97% year over year.

• How do I buy stock in Coya Therapeutics (COYA)?

  COYA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.